Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.
Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Pediatr Dermatol. 2022 Nov;39(6):960-966. doi: 10.1111/pde.15095. Epub 2022 Jul 24.
Pemphigus vulgaris (PV), an acquired autoimmune bullous disease, is caused by autoantibodies targeting desmosomal proteins in the skin and mucous membranes. Recent data from the adult PV population supports the use of rituximab, a chimeric anti-CD20 IgG1 antibody, as a primary treatment strategy, but limited data exist regarding treatment in the pediatric population. We report the case of a 13-year-old male with PV treated successfully with systemic corticosteroids and rituximab, and review the literature supporting the treatment of pediatric PV with rituximab.
寻常型天疱疮（PV）是一种获得性自身免疫性大疱病，由针对皮肤和黏膜中桥粒蛋白的自身抗体引起。来自成人 PV 人群的最新数据支持利妥昔单抗（一种嵌合抗 CD20 IgG1 抗体）作为主要治疗策略，但关于儿科人群的治疗数据有限。我们报告了一例成功接受全身皮质类固醇和利妥昔单抗治疗的 13 岁男性 PV 病例，并回顾了支持利妥昔单抗治疗儿科 PV 的文献。
